Update on the Clinical Utility of Fenofibrate in Mixed Dyslipidemias: Mechanisms of Action and Rational Prescribing

Overview

Journal Vasc Health Risk Manag

Publisher Dove Medical Press

Specialty Cardiology & Vascular Diseases

Date 2009 Feb 3

PMID 19183747

Citations 20

Authors

Michel Farnier

Affiliations

Soon will be listed here.

Abstract

Mixed dyslipidemia is a common lipid disorder characterized by the presence of an atherogenic lipoprotein phenotype due to abnormalities in various atherogenic and anti-atherogenic lipoproteins. Despite the link between the decrease of LDL-cholesterol by statin treatment and the prevention of cardiovascular disease, a high residual risk is observed in statin trials. This residual risk is partly explained by lipoprotein abnormalities other than LDL. Fenofibrate exerts a favorable effect on the atherogenic lipid profile of mixed dyslipidemia and can effectively reduce cardiovascular disease in patients with mixed dyslipidemia. Fenofibrate may offer important treatment alternatives as a second-line therapy in several circumstances: in combination with a statin for patients with mixed dyslipidemias not at goals on statin mono-therapy; in monotherapy for patients intolerant or with contraindication to statin therapy; and in combination with other drugs (ezetimibe, colesevelam) for patients with mixed dyslipidemias, known intolerance, or contraindication to statin and not at goals on fenofibrate monotherapy. However, the role of fenofibrate-statin therapy and of other therapies involving fenofibrate in cardiovascular risk reduction strategies remains to be established.

Citing Articles

Protein Kinases in Obesity, and the Kinase-Targeted Therapy.

Engin A Adv Exp Med Biol. 2024; 1460:199-229.

PMID: 39287853 DOI: 10.1007/978-3-031-63657-8_7.

High residual cardiovascular risk after lipid-lowering: prime time for Predictive, Preventive, Personalized, Participatory, and Psycho-cognitive medicine.

Reijnders E, van der Laarse A, Jukema J, M Cobbaert C Front Cardiovasc Med. 2023; 10:1264319.

PMID: 37908502 PMC: 10613690. DOI: 10.3389/fcvm.2023.1264319.

Peroxisomal Fitness: A Potential Protective Mechanism of Fenofibrate against High Fat Diet-Induced Non-Alcoholic Fatty Liver Disease in Mice.

Jiang S, Uddin M, Yu X, Piao L, Dorotea D, Oh G Diabetes Metab J. 2022; 46(6):829-842.

PMID: 35746892 PMC: 9723204. DOI: 10.4093/dmj.2021.0274.

Efficacy of a micronized, nanocrystal fenofibrate formulation in treatment of hyperlipidemia in dogs.

Munro M, Hulsebosch S, Marks S, Gilor C J Vet Intern Med. 2021; 35(4):1733-1742.

PMID: 34096101 PMC: 8295657. DOI: 10.1111/jvim.16190.

Successful fenofibrate therapy for severe and persistent hypertriglyceridemia in a boy with cirrhosis and glycerol-3-phosphate dehydrogenase 1 deficiency.

Matarazzo L, Ragnoni V, Malaventura C, Leon A, Colavito D, Vigna G JIMD Rep. 2020; 54(1):25-31.

PMID: 32685347 PMC: 7358666. DOI: 10.1002/jmd2.12125.

References

Vega G, Ma P, Cater N, Filipchuk N, Meguro S, Garcia-Garcia A . Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome. Am J Cardiol. 2003; 91(8):956-60. DOI: 10.1016/s0002-9149(03)00111-5. View

Ginsberg H, Bonds D, Lovato L, Crouse J, Elam M, Linz P . Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Am J Cardiol. 2007; 99(12A):56i-67i. DOI: 10.1016/j.amjcard.2007.03.024. View

Rosenson R, Huskin A, Wolff D, Helenowski I, Rademaker A . Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome. Atherosclerosis. 2008; 198(2):381-8. DOI: 10.1016/j.atherosclerosis.2007.12.007. View

Farnier M . Combination therapy with an HMG-CoA reductase inhibitor and a fibric acid derivative: a critical review of potential benefits and drawbacks. Am J Cardiovasc Drugs. 2004; 3(3):169-78. DOI: 10.2165/00129784-200303030-00003. View

McBride P . Triglycerides and risk for coronary heart disease. JAMA. 2007; 298(3):336-8. DOI: 10.1001/jama.298.3.336. View

Rubins H, Robins S, Collins D, Nelson D, Elam M, Schaefer E . Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention trial (VA-HIT). Arch Intern Med. 2002; 162(22):2597-604. DOI: 10.1001/archinte.162.22.2597. View

Farnier M, Roth E, Gil-Extremera B, Mendez G, Macdonell G, Hamlin C . Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia. Am Heart J. 2007; 153(2):335.e1-8. DOI: 10.1016/j.ahj.2006.10.031. View

Gordon D, Probstfield J, Garrison R, Neaton J, CASTELLI W, Knoke J . High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation. 1989; 79(1):8-15. DOI: 10.1161/01.cir.79.1.8. View

Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S . Triglycerides and the risk of coronary heart disease: 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2006; 115(4):450-8. DOI: 10.1161/CIRCULATIONAHA.106.637793. View

10.

Gustavson L, Schweitzer S, Koehne-Voss S, Achari R, Chira T, Esslinger H . The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite. J Clin Pharmacol. 2005; 45(8):947-53. DOI: 10.1177/0091270005278085. View

11.

Fazio S, Linton M . The role of fibrates in managing hyperlipidemia: mechanisms of action and clinical efficacy. Curr Atheroscler Rep. 2004; 6(2):148-57. DOI: 10.1007/s11883-004-0104-8. View

12.

Nordestgaard B, Benn M, Schnohr P, Tybjaerg-Hansen A . Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women. JAMA. 2007; 298(3):299-308. DOI: 10.1001/jama.298.3.299. View

13.

Durrington P, Tuomilehto J, Hamann A, Kallend D, Smith K . Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia. Diabetes Res Clin Pract. 2004; 64(2):137-51. DOI: 10.1016/j.diabres.2003.11.012. View

14.

Pan W, Gustavson L, Achari R, Rieser M, Ye X, Gutterman C . Lack of a clinically significant pharmacokinetic interaction between fenofibrate and pravastatin in healthy volunteers. J Clin Pharmacol. 2000; 40(3):316-23. DOI: 10.1177/00912700022008874. View

15.

Grundy S, Cleeman J, Merz C, Brewer Jr H, Clark L, Hunninghake D . Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004; 110(2):227-39. DOI: 10.1161/01.CIR.0000133317.49796.0E. View

16.

Buse J, Thomas Bigger J, Byington R, Cooper L, Cushman W, Friedewald W . Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods. Am J Cardiol. 2007; 99(12A):21i-33i. DOI: 10.1016/j.amjcard.2007.03.003. View

17.

Prueksaritanont T, Tang C, Qiu Y, Mu L, Subramanian R, Lin J . Effects of fibrates on metabolism of statins in human hepatocytes. Drug Metab Dispos. 2002; 30(11):1280-7. DOI: 10.1124/dmd.30.11.1280. View

18.

Gordon T, CASTELLI W, Hjortland M, Kannel W, DAWBER T . High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med. 1977; 62(5):707-14. DOI: 10.1016/0002-9343(77)90874-9. View

19.

Adkins J, Faulds D . Micronised fenofibrate: a review of its pharmacodynamic properties and clinical efficacy in the management of dyslipidaemia. Drugs. 1997; 54(4):615-33. DOI: 10.2165/00003495-199754040-00007. View

20.

Nissen S, Tuzcu E, Schoenhagen P, Brown B, Ganz P, Vogel R . Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004; 291(9):1071-80. DOI: 10.1001/jama.291.9.1071. View